Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

Open access
Fassas, Athanasios B.‐T., Muwalla, Firas, Berryman, Tanya, Benramdane, Riad, Joseph, Lija, Anaissie, Elias, Sethi, Rajesh, Desikan, Raman, Siegel, David, Badros, Ashraf, Toor, Amir, Zangari, Maurizio, Morris, Christopher, Angtuaco, Edgardo, Mathew, Sajini, Wilson, Carla, Hough, Aubrey, Harik, Sami, Barlogie, Bart, Tricot, Guido · 2002 · British Journal of Haematology

Abstract

Summary. Involvement of the central nervous system (CNS) by multiple myeloma, as defined by the detection of malignant plasma cells in the cerebrospinal fluid in the presence of suggestive symptoms, is considered extremely rare. We report on the characteristics of 18 such patients diagnosed and treated at the University of Arkansas over the last 10 years for an overall incidence of approximately 1%. Their evaluation revealed association of CNS involvement with unfavourable cytogenetic abnormalities (especially translocations and deletion of the chromosome 13), high tumour mass, plasmablastic morphology, additional extramedullary myeloma manifestations and circulating plasma cells. The presence of these features should alert clinicians to the possibility of CNS involvement. The outcome of these patients was extremely poor despite the use of aggressive local and systemic treatment including autologous stem cell transplants. Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2141.2002.03401.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

    Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 11×

    “Of the 14 patients who survived for more than 2 weeks after the involvement of CNS was documented, the CSF cleared in £ 2 weeks after initiation of treatment in eight patients, in 2–4 weeks in four patients, while the remaining two patients died without ever having cleared their CSF. Systemic treatment was administere…”
    MethodSelf-citation

Show all 1 references

Cited by

See all 167

Metadata

Authors
Fassas, A. B. ‐., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., Sethi, R., Desikan, R., Siegel, D., Badros, A., Toor, A., Zangari, M., Morris, C., Angtuaco, E., Mathew, S., Wilson, C., Hough, A., Harik, S., Barlogie, B., & Tricot, G.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2002-03-25
Volume
117
Issue
1
Pages
103-108
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2094451192
Cited by
167
References
1
FWCI
2.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. https://app.cochat.ai/papers/10.1046/j.1365-2141.2002.03401.x
The paper
Fassas, A. B. ‐., Muwalla, F., Berryman, T., Benramdane, R., Joseph, L., Anaissie, E., Sethi, R., Desikan, R., Siegel, D., Badros, A., Toor, A., Zangari, M., Morris, C., Angtuaco, E., Mathew, S., Wilson, C., Hough, A., Harik, S., Barlogie, B., & Tricot, G. (2002). Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2002.03401.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.